Your session is about to expire
← Back to Search
GEN-001 for Oral Squamous Cell Carcinoma
Study Summary
This trial is testing a new drug, GEN-001, to see if it is safe and has any effect on solid tumors that have progressed despite treatment with other drugs.
- Oral Squamous Cell Carcinoma
- Solid Tumors
- Non-Small Cell Lung Cancer
- Squamous Cell Carcinoma
- Bladder Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 trial • 19 Patients • NCT03006848Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does GEN-001 pose any potential hazards for humans?
"Due to the preliminary nature of GEN-001, Power assigned a score of 1 in regards to its safety profile. This is because there are limited data regarding both efficacy and protection from harm at this stage of development."
Could you provide a compendium of clinical trials involving GEN-001?
"The journey of GEN-001 began in 2014 at Port Macquarie Base Hospital, and 48 trials have since been completed. Currently 111 more are currently recruiting patients, with a significant amount of the studies being hosted out of Atlanta, Georgia."
Is this investigation a pioneering endeavor?
"A multitude of clinical trials involving GEN-001 are currently underway, spanning 1024 cities and 52 nations. The foremost trial for this medication was conducted by EMD Serono Research & Development Institute in 2014 - which included 204 patients and successfully concluded its Phase 2 drug approval procedure. Since said study's conclusion, 48 more have been carried out."
What is the scope of enrollment for this research trial?
"Affirmative, according to information hosted on clinicaltrials.gov the medical trial is actively enrolling patients at this time. It was initially published on October 26th 2020 and its last edits were made in August 1st 2022; with 93 candidates being sought from 3 different locations."
Is enrollment now open for this research endeavor?
"Confirmed - this clinical trial is currently open for enrollment. The study was initially made available to the public on October 26th 2020 and its details were most recently updated on August 1st 2022."
Share this study with friends
Copy Link
Messenger